Skip to main content
S 511 109th Congress Senate Health Abortion Administrative procedure Commerce Congress Congressional investigations Congressional reporting requirements Congressional veto Department of Health and Human Services Drug approvals Drugs Food and Drug Administration (FDA) Government Operations and Politics Government publicity Labeling Law

RU-486 Suspension and Review Act of 2005

Introduced: March 3, 2005 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 3, 2005
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2020-2021)
Mar 3, 2005
Sponsor introductory remarks on measure. (CR S2020)
Mar 3, 2005
Introduced in Senate
 Plain-English summary Congressional Research Service

RU-486 Suspension and Review Act of 2005 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.

Deems the drug misoprostol as misbranded under the Federal Food, Drug, and Cosmetic Act (FFDCA) if it bears labeling providing that the drug may be used for the medical termination of intrauterine pregnancy.

Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the reinstatement of the approved application for such drug if the report determines the approval to have been in accordance with FFDCA.

What's happening now March 3, 2005

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2020-2021)

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1